BCL-2抑制剂在急性髓性白血病临床应用新策略

吴迪; 李秋柏

doi:10.13201/j.issn.1004-2806.2022.05.004

BCL-2抑制剂在急性髓性白血病临床应用新策略

吴迪¹,
李秋柏^1, ,

- 华中科技大学同济医学院附属协和医院血液病研究所(武汉，430022)
基金项目:
十四五国家重点研发计划专项项目(No：2021YFA1101500)；国家自然科学基金重大研究计划(No：92049119)；国家自然科学基金面上项目(No：81974009)

详细信息

作者简介:
李秋柏，华中科技大学教授、主任医师，博士研究生导师，博士后合作导师，细胞外囊泡转化应用湖北省工程研究中心主任，十四五国家重点研发计划首席科学家。对老年急性髓性白血病等肿瘤和衰老相关疾病的基础和临床研究有着丰富经验，组织并完成多项新药临床试验。现任中国医药教育协会转化医学专委会常委、中国免疫学会血液免疫分会委员、中国抗癌协会血液病转化委员会青年委员、湖北省抗癌协会血液肿瘤专委会委员、湖北省抗癌协会血液肿瘤委员会白血病学组副组长、湖北省老年白血病研究协作组(HELSG)秘书长、中国老年学和老年医学学会老年病分会血液(湖北)专委会副主任委员。主持十四五国家重点研发计划干细胞专项1项、国家自然科学基金重大计划培育项目1项和面上项目3项，主持省部级课题4项及校自主创新基金2项，荣获湖北省科技进步奖一等奖2项，在Sci Transl Med、Leukemia、Nucleic Acids Res、Cancer Res、Theranostics、APS、Leuk Res等期刊上发表SCI论文30余篇

通讯作者: 李秋柏，E-mail：qiubaili@hust.edu.cn

中图分类号: R733.71

收稿日期: 2022-03-21

刊出日期: 2022-05-01

Novel clinical strategies of BCL-2 inhibitors in patients with acute myeloid leukemia

WU Di¹,
LI Qiubai^1, ,

More Information

Corresponding author: LI Qiubai, E-mail: qiubaili@hust.edu.cn

Received Date: 21 March 2022

Publish Date: 01 May 2022

摘要

- 急性髓性白血病 /
- BCL-2抑制剂 /
- 维奈克拉
- acute myeloid leukemia /
- BCL-2 inhibitors /
- venetoclax

HTML全文

参考文献(37)

[1]	中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性髓系白血病(非急性早幼粒细胞)诊疗指南(2021年版)[J]. 中华血液学杂志, 2021, 42(8): 617-623.
[2]	DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia[J]. N Engl J Med, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
[3]	Vachhani P, Wolach O, Garcia JS, et al. Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence(ARC)Initiative[J]. Blood, 2021, 138(Supplement 1): 1721. doi: 10.1182/blood-2021-146651
[4]	中国临床肿瘤学会白血病专家委员会. 维奈克拉治疗恶性血液病临床应用指导原则(2021年版)[J]. 白血病·淋巴瘤, 2021, 30(12): 710-718. doi: 10.3760/cma.j.cn115356-20210811-00175
[5]	Pratz KW, Jonas BA, Pullarkat V, et al. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine[J]. J Clin Oncol, 2022, 40(8): 855-865. doi: 10.1200/JCO.21.01546
[6]	Madarang E, Lykon J, Li WH, et al. Octogenarians with AML Can Have Durable Remissions with Venetoclax and Hypomethylating Agent Therapy Despite Significant Dose Reductions[J]. Blood, 2021, 138(Supplement 1): 1259. doi: 10.1182/blood-2021-151738
[7]	Manda S, Anz B. Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 1265. doi: 10.1182/blood-2021-144886
[8]	Mannis GN, Griffiths EA, Savona MR, et al. A Phase 1 Study Evaluating ASTX727(decitabine and cedazuridine)and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy[J]. Blood, 2021, 138(Supplement 1): 1245. doi: 10.1182/blood-2021-146264
[9]	李秋柏, 吴迪. 老年急性髓系白血病诊治进展[J]. 临床血液学杂志, 2021, 34(5): 308-313. doi: 10.13201/j.issn.1004-2806.2021.05.004
[10]	Daver N, Konopleva M, Maiti A, et al. Phase Ⅰ/Ⅱ Study of Azacitidine(AZA)with Venetoclax(VEN)and Magrolimab(Magro)in Patients(pts)with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia(AML)and Relapsed/Refractory(R/R)AML[J]. Blood, 2021, 138(Supplement 1): 371. doi: 10.1182/blood-2021-153638
[11]	Roboz GJ, Pabst T, Aribi A, et al. Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine(CVA)in Patients with Previously Untreated Acute Myeloid Leukemia(AML)Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study[J]. Blood, 2021, 138(Supplement 1): 369. doi: 10.1182/blood-2021-150371
[12]	Yilmaz M, Kantarjian H, Short N J, et al. Hypomethylating Agent(HMA)Therapy and Venetoclax(VEN)with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML[J]. Blood, 2021, 138(Supplement 1): 798. doi: 10.1182/blood-2021-154143
[13]	Short NJ, DiNardo CD, Daver N, et al. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase Ⅰ/Ⅱ Study[J]. Blood, 2021, 138(Supplement 1): 696. doi: 10.1182/blood-2021-153571
[14]	Wang HF, Mao LP, Xie WZ, et al. Venetoclax Combined with Daunorubicin and Cytarabine(DAV)As Induction Therapy in De Novo Young Adult Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 2334. doi: 10.1182/blood-2021-153257
[15]	Lachowiez C, DiNardo CD, Takahashi K, et al. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 701. doi: 10.1182/blood-2021-150457
[16]	Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial[J]. Lancet Haematol, 2021, 8(8): e552-e561. doi: 10.1016/S2352-3026(21)00192-7
[17]	Chen SN, Xie JD, Yang XF, et al. Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial[J]. Blood, 2021, 138(Supplement 1): 35. doi: 10.1182/blood-2021-153288
[18]	Brancati S, Gozzo L, Romano GL, et al. Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?[J]. Cancers(Basel), 2021, 14(1): 22.
[19]	Park S, Kim H, Cho B, et al. Comparison of Salvage Intensive Chemotherapy Versus Venetoclax Combined Regimen in Patients with Relapsed/Refractory Acute Myeloid Leukemia(AML)[J]. Blood, 2021, 138(Supplement 1): 2332. doi: 10.1182/blood-2021-152282
[20]	DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia[J]. J Clin Oncol, 2021, 39(25): 2768-2778. doi: 10.1200/JCO.20.03736
[21]	Tiong IS, Loo S, Abro EU, et al. A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C(VALDAC)to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 1261. doi: 10.1182/blood-2021-152583
[22]	Yilmaz M, Muftuoglu M, Kantarjian H, et al. Quizartinib(Quiz)with Decitabine(DAC)and Venetoclax(VEN)Is Highly Active in Patients(pts)with FLT3-ITD Mutated Acute Myeloid Leukemia(AML)-RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance[J]. Blood, 2021, 138(Supplement 1): 370. doi: 10.1182/blood-2021-153426
[23]	Daver N, Perl AE, Maly J, et al. Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 691. doi: 10.1182/blood-2021-150743
[24]	Chan SM, Cameron C, Cathelin S, et al. Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ⅰb/Ⅱ Enaven-AML Trial[J]. Blood, 2021, 138(Supplement 1): 1263. doi: 10.1182/blood-2021-153660
[25]	Borate U, Saultz JN, Kaempf A, et al. Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 2333. doi: 10.1182/blood-2021-152903
[26]	Schiller GJ, Finn L, Roboz GJ, et al. Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML[J]. Blood, 2021, 138(Supplement 1): 3412. doi: 10.1182/blood-2021-146018
[27]	Murthy GS, Kaufmann SH, Szabo A, et al. A Phase Ⅰ Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia(AML)[J]. Blood, 2021, 138(Supplement 1): 2347. doi: 10.1182/blood-2021-149351
[28]	Desikan SP, Kantarjian H, DiNardo CD, et al. A Phase Ⅰ/Ⅱ Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 3419. doi: 10.1182/blood-2021-151605
[29]	Zucenka A, Vaitekėnaitė V, Maneikis K, et al. Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting[J]. Blood, 2021, 138(Supplement 1): 3422. doi: 10.1182/blood-2021-144434
[30]	Daver N, Aribi A, Montesinos P, et al. Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia[J]. Blood, 2021, 138(Supplement 1): 372. doi: 10.1182/blood-2021-146503
[31]	Winters AC, Bosma G, Abbott D, et al. Outcomes Are Similar Following Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Patients Who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy[J]. Blood, 2021, 138(Supplement 1): 3957. doi: 10.1182/blood-2021-154392
[32]	Pollyea DA, Winters A, McMahon C, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60[J]. Bone Marrow Transplant, 2022, 57(2): 160-166. doi: 10.1038/s41409-021-01476-7
[33]	Gao F, Luo Y, Yu J, et al. Venetoclax Plus Hypomethylating Agent for the Salvage Treatment of Myeloid Malignancies Relapsing after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation[J]. Blood, 2021, 138(Supplement 1): 1825. doi: 10.1182/blood-2021-146364
[34]	Popat UR, Mehta RS, Bassett R, et al. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase Ⅱ Clinical Trial[J]. Blood, 2021, 138(Supplement1): 2879.
[35]	Foran JM. Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?[J]. Best Pract Res Clin Haematol, 2021, 34(4): 101335. doi: 10.1016/j.beha.2021.101335
[36]	Pollyea DA, Pratz KW, Wei AH, et al. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents[J]. Blood, 2021, 138(Supplement 1): 224. doi: 10.1182/blood-2021-145639
[37]	Shah MV, Chhetri R, Dholakia R, et al. Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy[J]. Blood, 2021, 138(Supplement1): 36.